Apex Biotechnology Corp. (TPE:1733)
28.00
-0.70 (-2.44%)
Nov 20, 2026, 1:30 PM CST
Apex Biotechnology Revenue
Apex Biotechnology had revenue of 428.30M TWD in the quarter ending September 30, 2026, a decrease of -2.04%. This brings the company's total for the last twelve months to 1.86B, down -5.22% year-over-year. In the year 2025, Apex Biotechnology had annual revenue of 1.94B with 5.00% growth. That makes Apex Biotechnology the 27,163rd largest company in the world by revenue and 1,272nd in Taiwan.
Revenue (ttm)
1.86B
Revenue Growth
-5.22%
P/S Ratio
1.51
Revenue / Employee
n/a
Employees
n/a
Market Cap
2.80B
Revenue by Geography
- United States 885.18M 45.5%
- Italy 535.58M 27.5%
- Austria 276.07M 14.2%
- Others 149.16M 7.7%
- Taiwan 75.86M 3.9%
- Mainland China 23.06M 1.2%
Fiscal year ended Dec 31, 2025 See the full Apex Biotechnology breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.94B | 92.70M | 5.00% |
| Dec 31, 2024 | 1.85B | 175.67M | 10.48% |
| Dec 31, 2023 | 1.68B | -567.64M | -25.29% |
| Dec 31, 2022 | 2.24B | 112.52M | 5.28% |
| Dec 31, 2021 | 2.13B | 126.32M | 6.30% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Hi-Clearance | 4.51B |
| InnoCare Optoelectronics | 3.07B |
| Wellell | 2.56B |
| OK Biotech | 1.72B |
| Dynamic Medical Technologies | 1.42B |
| WeLeader Biomedical | 1.27B |
| A Plus Biotechnology | 919.38M |
| Medimaging Integrated Solution | 744.42M |